May 28th 2022
The Access to Oncology Medicines Coalition brings together phamra companies and other organizations to help countries develop the capacity and access to essential cancer medicines.
May 27th 2022
This is the fifth biosimilar of Neulasta and the third biosimilar from Amneal to receive FDA approval.
May 27th 2022
The FDA has assigned a Prescription Drug User Fee Act target action date of Nov. 30, 2022. Regulators indicated they plan to hold an advisory committee meeting to discuss the application.
May 26th 2022
Tibsovo is the first therapy targeting cancer metabolism for patients with newly diagnosed IDH1-mutated acute myeloid leukemia.
May 26th 2022
Deficiencies at the contract manufacturing company are, for the second time, holding up approval of VP-102 to treat molluscum contagiosum, a mild skin infection.